Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

INTERVIEW: Ding plans Betta chances for Conmana in China

This article was originally published in Scrip

Executive Summary

China is home to the world's largest aging population – approximately 200 million people over the age of 60. As such, chronic diseases such as diabetes and cancer have been the target for big pharma companies in the country. Among them is Betta Pharma (Betta), a private company founded in 2003 by Dr Lieming Ding, a former board-certified physician in the US, and his partners.

You may also be interested in...



Chinese Appetite For Medtech Could Shrink In Face Of Uncertainty

The road to China's health-care market, once seen to be paved with gold by many medtech companies, is presenting more obstacles than before as a result of increased local competition and challenging policies. Multinationals and start-ups attending the recent China Healthcare Investment Conference discussed ways in which the medtech industry could continue to capitalize on this market's potential.

China’s Big And Small Next-Gen Sequencing Players Ride The Precision Medicine Wave

China is pushing ahead with initiatives in the precision medicine area, where it sees targeted diagnosis and treatment as particularly valuable in areas such as oncology, diabetes and cardiovascular disorders.

China's new biosimilars guideline: more flexibility, but stricter in parts

The China Food and Drug Administration has released the final version of its biosimilars guideline1.

Topics

Related Companies

UsernamePublicRestriction

Register

SC025483

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel